PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer
June 14, 2023 08:00 ET
|
PDS Biotechnology Corporation
14 patients in the immune checkpoint inhibitor naïve arm of VERSATILE-002 have experienced either a complete response or partial response on two consecutive scans, thus constituting a confirmed...
PDS Biotech Announces Plan to Initiate Phase 3 Study Evaluating PDS0101 in Combination with KEYTRUDA® in Head and Neck Cancer in 2023
March 30, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
February 27, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress
February 06, 2023 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
December 28, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Dec. 28, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Clinical Trial
November 14, 2022 07:00 ET
|
PDS Biotechnology Corporation
In the trial studying the combination of PDS0101 with standard-of-care chemoradiotherapy: 100% (9/9) showed clinical response (>60% tumor shrinkage at mid-point evaluation)89% (8/9) had no...
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable
October 27, 2022 08:00 ET
|
PDS Biotechnology Corporation
Jared Weiss, MD, Lead Investigator for the VERSATILE-002 clinical trial combining PDS0101 and KEYTRUDA®, presents interim data from the study Combination shows potential to achieve oncologists’ goals...
CORRECTING AND REPLACING -- PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
June 08, 2021 07:54 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by PDS Biotechnology Corporation (Nasdaq: PDSB), we've been informed by the company,...
PDS Biotech Announces Release of Interim Data for PDS0101 in NCI-Led Phase 2 Clinical Study in Oral Presentation at ASCO 2021 Annual Meeting
June 08, 2021 06:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...
PDS Biotechnology Set to Join Russell Microcap® Index
June 07, 2021 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 07, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s...